OPKO Health Files 13D/A for GeneDx Holdings Corp.

TL;DR

OPKO Health just updated its stake in GeneDx. Watch this space.

AI Summary

OPKO Health, Inc. has filed an amendment to its Schedule 13D, indicating a change in its beneficial ownership of GeneDx Holdings Corp. as of July 5, 2024. The filing details OPKO Health's holdings and intentions regarding GeneDx, a company formerly known as Sema4 Holdings Corp. and CM Life Sciences, Inc. The specific percentage of ownership and any new investment amounts are not detailed in this excerpt.

Why It Matters

This filing signals a potential shift in control or significant influence over GeneDx Holdings Corp. by OPKO Health, Inc., which could impact the company's strategic direction and stock performance.

Risk Assessment

Risk Level: medium — Filings like this can precede significant corporate actions or changes in market perception, introducing volatility.

Key Players & Entities

• OPKO HEALTH, INC. (company) — Filing party
• GeneDx Holdings Corp. (company) — Subject company
• Sema4 Holdings Corp. (company) — Former name of subject company
• CM Life Sciences, Inc. (company) — Former name of subject company

FAQ

Key Financial Figures

• $0.0001 — suer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securiti
• $26.4607 — the open market at prices ranging from $26.4607 to $31.20 per share for an aggregate sa
• $31.20 — rket at prices ranging from $26.4607 to $31.20 per share for an aggregate sale price o
• $2,457,285 — n aggregate sale price of approximately $2,457,285. ITEM 5. Interest in Securities of t

Filing Documents

• opk20240613_sc13da.htm (SC 13D/A) — 51KB
• 0001437749-24-022249.txt ( ) — 53KB

is amended by adding the following paragraph to the end of the item

Item 4 is amended by adding the following paragraph to the end of the item: In a series of transactions between July 1, 2024 and July 3, 2024, OPKO sold a total of 89,082 shares of GeneDx Common Stock on the open market at prices ranging from $26.4607 to $31.20 per share for an aggregate sale price of approximately $2,457,285. ITEM 5. Interest in Securities of the Issuer.

is deleted in its entirety and replaced with the following text

Item 5 is deleted in its entirety and replaced with the following text: (a) The Company's beneficial ownership of GeneDx Common Stock is as set forth in the table below: Name and Title of Beneficial Owner Number of Outstanding Shares Beneficially Owned Percentage of Outstanding Common Shares (1) OPKO Health, Inc. 3,469,521 13.27% ______________ (1) Based on 26,15,866 shares of GeneDx Common Stock (as defined herein) of the Issuer (as defined herein) outstanding on April 24, 2024, as set forth in the Issuer's DEF14A filed with the SEC (as defined herein) on April 29, 2024. (b) Items 7-10, inclusive, set forth on the cover page to this Amendment are hereby incorporated by reference in this Item 5. (c) In the last 60 days prior to the filing of this Amendment No. 3, OPKO sold a total of 89,082 shares of GeneDx Common Stock on the open market at prices ranging from $26.4607 to $31.20 per share for an aggregate sale price of approximately $2,457,285. The following table sets forth the information with regard to GeneDx Common Stock sold by OPKO on the open market in the last 60 days. Date Shares of Common Stock Aggregate Purchase Price Price Per Share 7/1/24 50,000 $ 1,331,669 $ 26.6340 7/2/24 25,000 $ 728,095 $ 29.1238 7/3/24 14,082 $ 397,491 $ 28.2269 (d) Except as described herein, no other person is known by OPKO to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any shares of the Issuer beneficially owned by them. (e) Not applicable. CUSIP No. 81663L200 Schedule 13D PAGE 4 of 4

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. OPKO Health, Inc. Dated: July 5, 2024 By: /s/ Steven D. Rubin Name: Steven D. Rubin Title: Executive Vice President - Administration

View Full Filing

View this SC 13D/A filing on SEC EDGAR